Corporate ActionJul 14, 2026, 04:03 PM
Crescent Biopharma Commences Public Offering of Shares
AI Summary
Crescent Biopharma, a clinical-stage biotechnology company, announced the commencement of an underwritten public offering. The offering includes ordinary shares and pre-funded warrants to purchase ordinary shares. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares. The proposed offering is subject to market and other conditions, with Jefferies, TD Cowen, Guggenheim Securities, and Cantor acting as joint book-running managers.
Key Highlights
- Crescent Biopharma commenced an underwritten public offering of its ordinary shares.
- The offering also includes pre-funded warrants to purchase ordinary shares.
- Underwriters have a 30-day option to purchase up to an additional 15% of ordinary shares.
- Jefferies, TD Cowen, Guggenheim Securities, and Cantor are joint book-running managers.
- LifeSci Capital is acting as passive book-running manager for the offering.
- The offering is pursuant to a shelf registration statement on Form S-3, effective July 10, 2026.
Price Impact
More from CBIO